SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as traders brace for a July 29th FDA Advisory Committee meeting, with significant community debate focused on whether the FDA will approve deramiocel for both skeletal and cardiac function or restrict it to a narrower cardiomyopathy label. Investors are closely monitoring briefing documents and potential regulatory outcomes, as high short interest and anticipation of a binary catalyst continue to drive intense volatility in the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility following the appointment of a new CEO and news of sNDA submissions for its Duchenne muscular dystrophy therapies, fueling intense community debate over leadership changes and institutional sentiment. Investors remain divided between optimism regarding potential buyout scenarios and frustration over the stock's long-term underperformance.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors weigh an expanded partnership with AT&T and a recent move to the Nasdaq against broader macro-driven volatility in speculative high-beta tech. While the community is actively debating the stock's valuation and the timing of commercial quantum adoption, many are focused on whether upcoming earnings will demonstrate that these strategic catalysts are successfully translating into revenue growth.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is currently trending as investors weigh its potential as a strategic Western supplier of critical rare earth elements against concerns over project timelines and share dilution. While community sentiment remains divided between bullish long-term outlooks on the Tanbreez deposit's assets and frustration over recent stock volatility, traders are closely monitoring potential infrastructure developments and government-backed initiatives within the critical minerals sector.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to new federal executive orders aimed at accelerating U.S. quantum technology leadership and secure data migration. The community is actively debating the stock's long-term potential versus concerns over high cash burn rates, recent insider selling, and the reliability of government-linked catalysts.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative CHMP opinion in Europe, though community sentiment remains resilient due to the drug's established U.S. FDA approval and upcoming reimbursement catalysts like the J-code activation. Discussions are heavily focused on the company's planned appeal, the potential for an independent expert group review to overturn the decision, and the belief that the stock's recent volatility is being driven by short-term sentiment rather than underlying fundamentals.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate whether the recent price action near key resistance levels signals a long-awaited macro bottom or a trap for the bulls. The community remains deeply polarized, with many users actively discussing the coin's utility and institutional adoption while others express frustration over its prolonged period of sideways performance compared to the broader crypto market.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending following a significant leadership transition as the company navigates ongoing market volatility and mixed reactions to its flagship product performance. Community discourse is heavily focused on whether this disruption and current price weakness signal a potential buyout opportunity or suggest underlying structural issues within the organization.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging following the announcement of a $53 million private placement, which has triggered heavy volume and intense speculation among traders. The community is actively debating the stock's massive single-day gains, with some participants expressing caution regarding potential dilution while others remain optimistic about the company's clinical pipeline.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil (UCO) is trending as traders closely monitor fluctuating geopolitical tensions, specifically developments surrounding US-Iran diplomatic efforts and potential disruptions in the Strait of Hormuz. The community remains divided, with active debates centered on whether current supply constraints support a bullish outlook or if potential peace agreements and increasing renewable energy adoption will trigger a significant correction in crude prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phillips Edison & Company, Inc. (PECO) Beats Q2 FFO Estimates

Phillips Edison & Company (PECO) delivered FFO and revenue surprises of +1.47% and -0.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Phillips Edison & Company (PECO) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Phillips Edison & Company (PECO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Seeking Clues to Phillips Edison & Company (PECO) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Get a deeper insight into the potential performance of Phillips Edison & Company (PECO) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

PECO Crosses Above Average Analyst Target

In recent trading, shares of Phillips Edison & Co Inc (Symbol: PECO) have crossed above the average analyst 12-month target price of $43.85, changing hands for $44.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

Zacks Industry Outlook Highlights Phillips Edison, Tanger and American Assets Trust

Retail REITs are benefiting from strong leasing demand and limited new supply, with Phillips Edison, Tanger and American Assets Trust positioned to capitalize.

3 Retail REITs Poised to Benefit From Leasing Strength and Low Supply

Phillips Edison, Tanger and American Assets Trust stand to gain as essential retail demand, tight supply and strong leasing support growth.

Phillips Edison & Company, Inc. (PECO) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Phillips Edison & Company (PECO) have what it takes? Let's find out.

Is Holding Simon Property Stock Still Smart Move for Your Portfolio?

SPG benefits from strong leasing, redevelopment and liquidity, but debt and e-commerce remain key risks.

Phillips Edison & Company (PECO) Upgraded to Buy: Here's Why

Phillips Edison & Company (PECO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Holding Essex Property Trust Still Smart Move for Your Portfolio?

ESS benefits from strong West Coast rental demand, high occupancy and a solid balance sheet, though Seattle weakness and debt remain risks.

Phillips Edison & Co., Inc. is a real estate investment trust, which engages in the ownership and operation of shopping centers. It also offers an investment management business providing property management and advisory services. Its portfolio consists of well-occupied, grocery-anchored neighborhood and community shopping centers having a mix of national, regional, and local retailers offering necessity-based goods and services. The company was founded by Jeffrey S. Edison and Michael C. Phillips in 1991 and is headquartered in Cincinnati, OH.

Phillips Edison & Company Inc - Ordinary Shares - New

Neutral Sentiment

U.S. - Iran negotiations

Earnings

FOMC meeting

Other (drop a comment)

This week brings a Federal Reserve rate decision, Q2 GDP and PCE inflation data, and earnings from $MSFT, $META, $AAPL, and $AMZN. What will be the biggest driver of the market this week? Vote and explain your reasoning in the comments.

What will be the main driver of the market this week? 
 
Explain your reasoning in the comments.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PECOPhillips Edison & Company Inc - Ordinary Shares - New

Latest PECO News